Study of dilated cardiomyopathy and phospholamban
10.3760/cma.j.issn.1673-4408.2011.01.019
- VernacularTitle:受磷蛋白与扩张型心肌病的相关研究
- Author:
Xueming ZHENG
- Publication Type:Journal Article
- Keywords:
Dilated cardiomyopathy;
Phospholamban;
Ca2 + ATPase;
Cardiac resynchronization therapy
- From:
International Journal of Pediatrics
2011;38(1):53-55
- CountryChina
- Language:Chinese
-
Abstract:
It is discovered that dilated cardiomyopathy (DCM) is not only affected by environmental factors, but also has a significant genetic basis. Phospholamban ( PLN ), one of these related genes, is a prominent regulator of myocardial contractility, It is an important regulatory factor for heart muscle contraction. It can regulate the activity of sarcoplasmic reticulum Ca2+ ATPase ( SERCA2a), and inhibit SERCA2a activity through restricting the Ca2+ flow in myocardial cells. The activity of SERCA2a can be improved by lowering the expression of PLNmRNA, and the affinity of SERCA2a is strengthened, so that the heart's activity is improved.
